Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap |
|---|
| Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
RE REGN REGENERON PHARMACEUTICALS, INC. FY ended Dec 31, 2025 | $794.19 | $74.98B | $69.81B | $14.34B | $5.62B | $4.50B | 19.15x | 5.23x | 12.32x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 16.48x | 5/6 | -$13.49B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 10.39x | 6/6 | $29.82B | $118.69 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 17.80x | 6/6 | -$20.22B | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
RE REGN REGENERON PHARMACEUTICALS, INC. FY ended Dec 31, 2025 | $794.19 | $74.98B | $69.81B | $14.34B | $5.62B | $4.50B | 19.15x | 5.23x | 12.32x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
VR VRTX VERTEX PHARMACEUTICALS INC / MA FY ended Feb 06, 2026 | $541.69 | $137.30B | $134.75B | $12.00B | $4.88B | $3.95B | 35.36x | 11.44x | 27.38x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 16.48x | 5/6 | -$13.49B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 10.39x | 6/6 | $29.82B | $118.69 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 17.80x | 6/6 | -$20.22B | — | Target fundamentals do not produce a usable positive equity value. |
